| Literature DB >> 30112097 |
Mrityunjay K Sharma1,2, Roopashri B Acharya2, Chinmay A Shukla1,2, Amol A Kulkarni1,2.
Abstract
The multistep flow synthesis of complex molecules has gained momentum over the last few years. A wide range of reaction types and conditions have been integrated seamlessly on a single platform including in-line separation as well as monitoring. Beyond merely getting considered as 'flow version' of conventional 'one-pot synthesis', multistep flow synthesis has become the next generation tool for creating libraries of new molecules. Here we give a more 'engineering' look at the possibility of developing a 'unified multistep flow synthesis platform'. A detailed analysis of various scenarios is presented considering 4 different classes of drugs already reported in the literature. The possible complexities that an automated and controlled platform needs to handle are also discussed in detail. Three different design approaches are proposed: (i) one molecule at a time, (ii) many molecules at a time and (iii) cybernetic approach. Each approach would lead to the effortless integration of different synthesis stages and also at different synthesis scales. While one may expect such a platform to operate like a 'driverless car' or a 'robo chemist' or a 'transformer', in reality, such an envisaged system would be much more complex than these examples.Entities:
Keywords: automation; continuous flow synthesis; cybernetics; multistep flow synthesis; unified platforms
Year: 2018 PMID: 30112097 PMCID: PMC6071694 DOI: 10.3762/bjoc.14.166
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Reactions and corresponding flow synthesis set-up from the literature.
| reaction name and flow set-up |
A few important drug molecules synthesized in multistep continuous flow.
| molecules and reaction/separation steps | end product | remarks |
| olanzapine (Zyprexa) [ | • antipsychotic drug | |
| tamoxifen [ | • breast cancer drug | |
| amitriptyline [ | • antidepressant drug | |
| rufinamide [ | • anticonvulsant drug | |
| artemisinin [ | • antimalarial drug | |
| telemisartan [ | • hypertension drug | |
| ibuprofen [ | • nonsteroidal anti-inflammatory drug | |
| ( | • anti-inflammatory drug and selective phosphodiesterase 4 (PDE4) inhibitor | |
| (±)-pregabalin [ | • used as a therapeutic agent for nervous system disorders such as epilepsy, anxiety disorder, and neuropathic pain | |
Definition of the specific terms used in the article.
| terms as used in this article | meaning/relevance |
| 1. reactor | the section of the platform used for carrying out reactions. Usually, reactors are followed by separators (for extraction, distillation, chromatographic separation, crystallization, etc.). |
| 2. instrument | wireless or cabled electronic unit that interfaces with the reactor and separator to facilitate monitoring and/or measurement and/or control. |
| 3. equipment | an electronic unit that facilitates dosing of gas, liquid and solid. |
| 4. component | connecting joints between reactor(s), instruments and equipment. These will include fittings, connectors, valves, etc. |
| 5. module | an assembly of all the above segments to facilitate flow synthesis along with monitoring and control (1–4). |
| 6. variables and parameter | set of conditions (set points or variables) that are used for optimizing a specific reaction section or the entire sequence of reactions. |
| 7. stage | individual unit operations (viz. pre-heating, mixing, reaction, quenching, separation, etc.). |
| 8. number of steps | number of reactions (chemical transformations) in a sequence to obtain the final product. |
| 9. synthesis sequence | a sequence of reactions and unit operations (stages) in the synthesis path for the specific final product. |
Multistep synthesis case studies selected for the article.
Figure 1Key features of different approaches for unified multistep synthesis platform.
Figure 2Schematic representation of a unified platform for the flow synthesis (P1–P14 pumps, PBR packed bed reactor, HE1 heat exchanger, H1 heater, S1 and S2 separator, E1 extractor, TR1–TR4 tubular reactor, CH charcoal, CT1 crystallization tank, T1–T3 tanks, F1 filtration).
Conventional path for the synthesis of different intermediates based on approach 1.
| intermediate | multistep synthesis flow path |
| prexasertib monolactate monohydrate | P1+P2→HE1→TR1→E1→TR2→TR3→RE1→T2→TR4→F1→T1 |
| aliskiren hemifumatate | P1+P2→R1→S1→S2→TR4→S1→PBC→C1→S2→T2 |
| diphenhydramine hydrochloride | P1+P2→R1→H1→BPR→CH→S1 |
| lidocaine hydrochloride | P1+P2→R1→R2→BPR→CH→S1 |
| diazepam | P1+P2→R1→R2→BPR→CH→S1 |
| fluoxetine hydrochloride | P1+P2→R1→R2→S1→S2→R3→S1→H1→R2→T1 |
| ricociclib | P1+P2→R1→R2→S1→R4→T1 |
| rolipram | P1+P2→PBR1→X→TR1→PBR2→PBR3→Y→Z→T3 |
Components required for the synthesis of the above API’s [pumps (P), reactor (R), heat exchanger (HEx), heater (H), back pressure regulator (BPR), packed/fixed bed reactor (PBR/FBR), separator (S), charcoal adsorption cartridge (CA), liquid–liquid extractor (LLEx)]
| name of API’s | P | R | HEx | H | BPR | PBR/FBR | S | CA | LLEx |
| diphenhydramine hydrochloride | 4 | 1 | – | 1 | 1 | – | 1 | 1 | – |
| lidocaine hydrochloride | 5 | 2 | – | – | 1 | 1 | 1 | – | – |
| diazepam | 4 | 2 | – | – | 1 | 1 | 1 | 1 | – |
| fluoxetine hydrochloride | 11 | 4 | – | 1 | 4 | – | 4 | – | – |
| aliskiren hemifumarate | 14 | 2 | – | – | – | 1 | 5 | – | – |
| ricociclib | 4 | 2 | – | – | – | – | 2 | – | 2 |
| rolipram | 7 | 1 | 5 | ||||||
| prexasertib monolactate monohydrate | 20 | 3 | 1 | – | – | 1 | – | 2 | |
Figure 3Layout of a unified synthesis platform (including all the component) for multiple drug molecules (approach 2) R – coil reactor/packed bed reactor/scavenger, P – pump, HE – heat exchanger, CSTR – stirred tank reactor/crystallizer/dilution tank, T – storage tank, F – filter, S – gravity-based separator, D – dryer, FP – filter press, MS – membrane separator, E – extruder, BPR – back pressure regulator.
Figure 4Layout for synthesis of 4 molecules on a single platform (approach 2).
Scheme 1The overall process for the synthesis of diphenhydramine hydrochloride.
Figure 5Approach 3 for a unified platform for multistep synthesis. M1–M9 = mixers, R1–R4 = tubular reactors, R5–R8 = packed bed reactor, R9 = stirred tank reactor, T1–T8 = Intermediate storage tanks, S1–S3 = adsorption columns, S4–S6 = extraction columns/gravity-based separator, S7–S9 = membrane separator/Filter, S10–S11 = evaporator, S12 = rotary drum dryer, S13 = vacuum screw dryer, S14 = extruder.
Sequence of unit operations for various pharmaceutical products by approach 3.
| reference | product | reactors/equipment/ | sequence of unit operations as per approach 3 (see |
| Tsubogo et al. [ | ( | • packed bed reactors (4) | M5→R5→T5→S1→M6→R6→T6→M7→ |
| Pellegatti et al. [ | ribociclib | • flow reactors (2) | M1→R1→M2→R2→S4→T1→M3→R3→ |
| Cole et al. [ | prexasertib monolactate monohydrate | • flow reactors (4) | M1→R1→T1→S4→T2→S5→T3→S6→T4 |
| Adamo et al. [ | fluoxetine hydrochloride | • flow reactors (4) | M1→R1→T1→S7→T2→S8→R2→T3→ |
| diazepam | • flow reactors (2) | M1→R1→M2→R2→T1→R5→S4→S1→ | |
| lidocaine hydrochloride | • flow reactors (2) | M1→R1→N2→R2→T1→R5→ | |
| diphenhydramine hydrochloride | • flow reactor (1) | M1→R1→T1→R5→S4→S1→downstream | |
| Mascia et al. [ | aliskiren hemifumarate | • flow reactors (2) | M1→R1→T1→S4→T2→T3→S7→T4→M2 |